BRD2 细胞状态可塑性的odomain介导调节调节了 Glioblastoma 细胞母细胞瘤治疗反应
Raghavendra Vadla1, Brett Taylor1,2, Yohei Miyake1
1Division of Regenerative Medicine, Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Neuro-oncology
|July 21, 2025
概括
这项研究确定BRD2是质母细胞瘤 (GBM) 细胞可塑性和治疗耐药性的关键调节者. 用选择性抑制剂向BRD2显示出克服辐射抵抗和改善GBM患者结果的希望.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
背景情况:
- 质母细胞瘤 (GBM) 具有显著的细胞状态可塑性,有助于治疗耐药性和瘤进展.
- 表观遗传机制是GBM可塑性的核心,但关键的调节器和治疗点仍然难以捉摸.
研究的目的:
- 调查BRD2在GBM中介介介介酶 (MES) 过渡中的作用.
- 评估在GBM治疗中准BRD2,特别是其原体的治疗潜力.
主要方法:
- 使用患者衍生的GBM异种移植模型,CRISPR技术和RNA-seq.
- 采用了体外和体内模型来研究BRD2功能和BET抑制剂的影响.
- 研究了PTEN损失对BRD2招募和MES基因表达的影响.
主要成果:
- 失去PTEN促进了BRD2对MES基因促进者的招募,这对于维持MES表型至关重要.
- 在异种移植模型中,BRD2基因的遗传失活化逆转了MES过渡,增强了辐射敏感性,并改善了生存率.
- 一种穿透大脑的BRD2选择性抑制剂抑制了MES表型并增加了GBM干细胞的辐射敏感性.
结论:
- BRD2被确定为通过其原体通过GBM细胞状态可塑性的关键调解者.
- 用选择性抑制剂向BRD2是一种有希望的策略,可以提高放射治疗的疗效,并改善GBM患者的治疗结果.
更多相关视频
09:36Live-Cell Imaging Assays to Study Glioblastoma Brain Tumor Stem Cell Migration and Invasion
Published on: August 29, 2018
10.4K
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
8.4K
相关概念视频
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:23Negative Regulator Molecules
36.0K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.0K